Deltex Medical Regulatory News (DEMG)

28 Mar 2008 07:02

Deltex Medical Group PLC28 March 2008 Deltex Medical Group plc First NHS National Technology Adoption Hub sales 28 March 2008 - Deltex Medical Group plc ("Deltex Medical" or the "Company"),the UK's leading haemodynamic monitoring company, announced in October 2007 thatits CardioQ(TM) system was one of the first products to be selected under the NHS National Technology Adoption Hub (NTAH) programme. The Company today announces that it has now made its first sale in connection with the NTAH. The NTAH has been established as a key element of the NHS innovation agendawhich is aimed at ensuring that NHS patients in England benefit earlier fromproven new medical technologies. The NTAH website iswww.technologyadoptionhub.nhs.uk. The Whittington Hospital in London is one of three hospitals participating inthe first phase of the NTAH project. It has purchased four CardioQ monitors foruse in its operating theatres, which are in addition to the five that it alreadyowns, which are primarily deployed in Intensive Care. The Company expects thehospital to soon increase its regular probe ordering level as it implements itsplans to expand its use of CardioQ. Deltex Medical's Chief Executive, Andy Hill commented: "This order means that the Whittington Hospital now owns sufficient monitors tomove forward with implementing the CardioQ across all those groups of patientswhere benefit has already been proven." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6000Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ(TM) monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already around 1,500 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange